Common · Knowledge
Nimodipine
Chemical compound
Nimodipine, sold under the brand name Nimotop among others, is a calcium channel blocker used in preventing vasospasm secondary to subarachnoid hemorrhage (a form of cerebral hemorrhage). It was originally developed within the calcium channel blocker class as it was used for the treatment of high blood pressure, but is not used for this indication.
Read more
It was patented in 1971 and approved for medical use in the United States in 1988. It was approved for medical use in Germany in 1985. Because it has some selectivity for cerebral vasculature, nimodipine's main use is in the prevention of cerebral vasospasm and resultant ischemia, a complication of subarachnoid hemorrhage (a form of cerebral bleed), specifically from ruptured intracranial berry aneurysms irrespective of the patient's post-ictus neurological condition. Its administration begins within 4 days of a subarachnoid hemorrhage and is continued for three weeks. If blood pressure drops by over 5%, dosage is adjusted. There is still controversy regarding the use of intravenous nimodipine on a routine basis. A 2003 trial found nimodipine was inferior to magnesium sulfate in preventing seizures in women with severe preeclampsia. Nimodipine is not regularly used to treat head injury.
Text: Wikipédia, CC BY-SA 4.0. · Image: Vaccinationist (Public domain) ·